

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A method of stimulating an immune response, said method comprising administering a composition comprising an isolated polypeptide comprising an amino acid sequence having at least 98% identity to the entirety of residues 8 to 598 of SEQ ID NO: 140, and thereby stimulating an immune response specific for the polypeptide of residues 8 to 598 of SEQ ID NO: 140.
2. (Previously Presented) The method of claim 1, wherein the composition further comprises a physiologically acceptable carrier.
3. (Previously Presented) The method of claim 1, wherein the composition further comprises an adjuvant.
4. (Previously Presented) The method of claim 3, wherein the adjuvant induces an immune response predominantly of the Th1 type.
5. (Previously Presented) The method of claim 4, wherein the adjuvant is selected from the group consisting of monophosphoryl lipid A, 3-de-O-acylated monophosphoryl lipid A, CpG-containing oligonucleotides, saponins, QS21, and combinations thereof.
6. (Previously Presented) The method of claim 3, wherein the adjuvant is an aminoalkyl glucosaminide 4-phosphate.
7. (Previously Presented) The method of claim 6, wherein the aminoalkyl glucosaminide 4-phosphate is RC-529.
8. (Currently Amended) The method of claim 1, wherein the composition comprises residues 8 to 598 of the polypeptide of SEQ ID NO: 140.